Three prescription products, domperidone tablets, lodoxamide trometamol eye-drops
and triamcinolone acetonide nasal spray, become pharmacy medicines on November
16.
Domperidone becomes a pharmacy medicine with a maximum dose of 10mg and a maximum
daily dose of 40mg in packs containing no more than 200mg of domperidone for
the treatment of post-prandial symptoms of excessive fullness, nausea, epigastric
bloating and belching, occasionally accompanied by epigastric discomfort and
heartburn. Lodoxamide trometamol eye-drops (equivalent to 0.1 per cent lodoxamide)
for the treatment of allergic conjunctivitis in people aged over four years
also become P, as does triamcinolone acetonide nasal spray for the treatment
of seasonal allergic rhinitis (packs will be restricted to 3.575mg of active
ingredient with a maximum dose of 110mg per nostril per day for three months).
On the same date, azelastine hydrochloride becomes available as a pharmacy medicines
to treat perennial allergic rhinitis, the maximum pharmacy pack size of domperidone
maleate rises to 200mg, the maximum paediatric dose of paracetamol rises to
250mg and the maximum pharmacy pack size of ibuprofen for external use is cut
to 50g.
Twelve products which are classified as prescription medicines by their marketing
authorisations are added to the POM Order. They are cabergoline, cefprozil,
indapamide, lansoprazole, lercanidipine hydrochloride, meloxicam, pantoprazole
sodium, penciclovir, tamsulosin hydrochloride, ticlodipine hydrochloride, tiludronate
disodium and toremifene.
The list of products which may be administered by state registered paramedics
is extended to include ergometrine maleate 500mcg per 1ml combined with oxytocin
5 IU per 1ml, benzylpenicillin, frusemide, metoclopramide, morphine sulphate
and streptokinase.